Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
CTV-P consensus: CTV-P1 = GTV-P + 5 mm, CTV-P2 = GTV-P + 10 mm, both anatomically edited, for definitive RT of laryngeal, hypopharyngeal, oropharyngeal and oral cavity SCC.
This is a day of contouring guidelines with no outcome data. Four H&N documents set primary CTV margins (GTV + 5 and 10 mm), elective neck levels, node-level boundaries and 5 mm / ≥30 mm nerve-path CTVs for V1/V2/V3 PNI. ESTRO ACROP LA-NSCLC discourages elective nodal coverage beyond the hilum and adjacent stations. Margins rest largely on expert opinion.
read the full digest →Studies · 256
- Trigeminal nerve (V) contouring guidelines in head and neck cancersPractical CTV guidance for PNI along V1/V2/V3: CTV-P1 = GTV + 5 mm along nerve; CTV-P2 = nerve path ≥30 mm, skull base often recommended.
- Neck node level delineation: 2013 update consensus guidelinesJoint DAHANCA/EORTC/HKNPCSG/NCIC CTG/NCRI/RTOG/TROG CT atlas defines neck node levels Ia through Xb by axial-CT boundaries, Robbins-modified nomenclature.
- CTV-P delineation consensus guidelines (laryngeal, hypopharyngeal, oropharyngeal, oral cavity SCC)CTV-P1 = GTV-P + 5 mm and CTV-P2 = GTV-P + 10 mm, both anatomically edited, for definitive RT of laryngeal, hypopharyngeal, oropharyngeal and oral cavity SCC.
- Target volume selection and delineation (T and N) for primary RT of oral cavity, oropharyngeal, hypopharyngeal and laryngeal SCCElective neck levels II-IVa for N0 pharyngolaryngeal SCC and Ib-V for N2a-b/N3; primary CTV is GTV + 5 and 10 mm, anatomically edited.
- ESTRO ACROP target volume guidelines for locally advanced NSCLCGraded consensus (M/R/O/D) for LA-NSCLC contouring: PET-CT-defined nodal GTV, CTV +5–8 mm, elective nodal coverage beyond hilum/adjacent stations discouraged.
- Radiosurgery Society SBRT guide for localized prostate cancer40 Gy/5fx to prostate + proximal 1cm SV as worked example; large gland and poor baseline IPSS framed as counselling issues, not SBRT contraindications.
- ESTRO ACROP Delphi: salvage SBRT for intraprostatic relapseConsensus on 14/40 items (35%) for intraprostatic relapse after RT: focal GTV-based CTV, no concurrent ADT; dose, fractionation, OAR limits unresolved.
- ASCO guideline: imaging for advanced prostate cancerNGI offered only when salvage or a change in care is live. 4.4 (salvage RT contemplated after RP) is the sole high-quality, strong recommendation.
- ESGO/ESTRO/ESP endometrial carcinoma guidelines~3% of endometrial carcinomas are Lynch-related; the guideline advises MMR IHC or MSI testing in all EC regardless of histology (III, B) and four-test molecular classification.
- ABS gynecologic HDR brachytherapy fractionation compendiumReference HDR schedules with EQD2 for cervix, endometrium and vagina. Cervix HR-CTV D90 goal 85-95 Gy EQD2(10); no cuff regimen ranked above another.
- ASCO-ASTRO-SSO Hereditary Breast Cancer GuidelineJoint consensus guideline: RT should not be withheld in BRCA1/2, ATM or other moderate-penetrance carriers; intact-breast RT is contraindicated in germline TP53 carriers.
- ASTRO-ASCO-SSO PMRT GuidelinePMRT is recommended for pN1, any pT4, ypN1 and cT4/cN2-3 after NST, and conditional for pT3N0 and cT1-3N1/cT3N0 ypN0. Moderate hypofractionation is preferred.